[go: up one dir, main page]

WO2009143345A3 - Conjugués agent-protéine désactivant des acides nucléiques et leur utilisation pour traiter des troubles liés au vhc - Google Patents

Conjugués agent-protéine désactivant des acides nucléiques et leur utilisation pour traiter des troubles liés au vhc Download PDF

Info

Publication number
WO2009143345A3
WO2009143345A3 PCT/US2009/044840 US2009044840W WO2009143345A3 WO 2009143345 A3 WO2009143345 A3 WO 2009143345A3 US 2009044840 W US2009044840 W US 2009044840W WO 2009143345 A3 WO2009143345 A3 WO 2009143345A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
related disorders
protein conjugates
treating hcv
silencing agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/044840
Other languages
English (en)
Other versions
WO2009143345A2 (fr
Inventor
Gregory J. Babcock
Donna M. Ambrosino
Robert W. Finberg
Phillip D. Zamore
Teresa Broering
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Massachusetts Amherst
Original Assignee
University of Massachusetts Amherst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Massachusetts Amherst filed Critical University of Massachusetts Amherst
Publication of WO2009143345A2 publication Critical patent/WO2009143345A2/fr
Publication of WO2009143345A3 publication Critical patent/WO2009143345A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un procédé d'utilisation d'un complexe ou d'une molécule comportant un fragment de ciblage pour distribuer efficacement une seconde molécule au virus de l'hépatite C (VHC) ou à une cellule infectée ou présentant le potentiel d'être infectée par le VHC, conduisant à la prévention, à l'immunisation, à l'inhibition ou à la guérison d'une infection par le VHC, ou d'autres effets bénéfiques liés à une infection par le VHC.
PCT/US2009/044840 2008-05-22 2009-05-21 Conjugués agent-protéine désactivant des acides nucléiques et leur utilisation pour traiter des troubles liés au vhc Ceased WO2009143345A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12866508P 2008-05-22 2008-05-22
US61/128,665 2008-05-22

Publications (2)

Publication Number Publication Date
WO2009143345A2 WO2009143345A2 (fr) 2009-11-26
WO2009143345A3 true WO2009143345A3 (fr) 2010-08-12

Family

ID=41226108

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/044840 Ceased WO2009143345A2 (fr) 2008-05-22 2009-05-21 Conjugués agent-protéine désactivant des acides nucléiques et leur utilisation pour traiter des troubles liés au vhc

Country Status (1)

Country Link
WO (1) WO2009143345A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3489684B1 (fr) * 2017-11-27 2024-06-26 Miltenyi Biotec B.V. & Co. KG Procédé de photoblanchiment de cellules colorées
CN109694868A (zh) * 2018-12-27 2019-04-30 合肥中科干细胞再生医学有限公司 一种抑制sFRP1基因表达的siRNA及其应用
WO2021237160A2 (fr) * 2020-05-22 2021-11-25 City Of Hope Conjugués d'acide nucléique de phosphorothioate comprenant des enzymes d'édition génique
KR20230043115A (ko) * 2020-06-24 2023-03-30 사프렘 테크놀로지스 비.브이. 히드라존에 기반한 사포닌 유도체
EP4171644A2 (fr) * 2020-06-24 2023-05-03 Sapreme Technologies B.V. Dérivés de saponine à fenêtre thérapeutique améliorée
CN116801909A (zh) * 2020-12-02 2023-09-22 S·鲍默 静电纳米颗粒及其用途
CN112924665B (zh) * 2021-02-19 2023-10-03 山东莱博生物科技有限公司 一种抗体辣根过氧化物酶标记物及其制备与应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040209831A1 (en) * 2002-02-20 2004-10-21 Mcswiggen James RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (siNA)
US20060281175A1 (en) * 2002-02-20 2006-12-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
WO2007069068A2 (fr) * 2005-12-16 2007-06-21 Diatos Conjugués peptidiques de pénétration cellulaire pour la délivrance d'acides nucléiques dans une cellule
WO2008108918A1 (fr) * 2007-02-21 2008-09-12 University Of Massachusetts Utilisation d'anticorps humains contre le virus de l'hépatite c (vhc)

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040209831A1 (en) * 2002-02-20 2004-10-21 Mcswiggen James RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (siNA)
US20060281175A1 (en) * 2002-02-20 2006-12-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
WO2007069068A2 (fr) * 2005-12-16 2007-06-21 Diatos Conjugués peptidiques de pénétration cellulaire pour la délivrance d'acides nucléiques dans une cellule
WO2008108918A1 (fr) * 2007-02-21 2008-09-12 University Of Massachusetts Utilisation d'anticorps humains contre le virus de l'hépatite c (vhc)

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BROERING TERESA J ET AL: "Identification and characterization of broadly neutralizing human monoclonal antibodies directed against the E2 envelope glycoprotein of hepatitis C virus", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US LNKD- DOI:10.1128/JVI.01138-09, vol. 83, no. 23, 1 December 2009 (2009-12-01), pages 12473 - 12482, XP008122678, ISSN: 0022-538X, [retrieved on 20090916] *
BROERING TERESA J ET AL: "Neutralizing human monoclonal antibodies specific for a highly conserved linear epitope of HCV E2 protein", GASTROENTEROLOGY; DIGESTIVE DISEASE WEEK MEETING/108TH ANNUAL MEETING OF THE AMERICAN-GASTROENTEROLOGICAL-ASSOCIATION; WASHINGTON, DC, USA; MAY 19-24, 2007, ELSEVIER, PHILADELPHIA, PA LNKD- DOI:10.1016/S0016-5085(07)60010-9, vol. 132, no. 4, suppl. 2, 1 April 2007 (2007-04-01), pages A782, XP008122681, ISSN: 0016-5085, [retrieved on 20070712] *
DE PAULA DANIEL ET AL: "Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting.", RNA (NEW YORK, N.Y.) APR 2007 LNKD- PUBMED:17329355, vol. 13, no. 4, April 2007 (2007-04-01), pages 431 - 456, XP002585509, ISSN: 1355-8382 *
LIU BIN: "Exploring cell type-specific internalizing antibodies for targeted delivery of siRNA", BRIEFINGS IN FUNCTIONAL GENOMICS AND PROTEOMICS, HENRY STEWART, LONDON, GB LNKD- DOI:10.1093/BFGP/ELM015, vol. 6, no. 2, 31 July 2007 (2007-07-31), pages 112 - 119, XP009107654, ISSN: 1473-9550 *
SONG ERWEI ET AL: "Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors", NATURE BIOTECHNOLOGY, vol. 23, no. 6, June 2005 (2005-06-01), pages 709 - 717, XP002585508, ISSN: 1087-0156 *
WATANABE ET AL: "Liver target delivery of small interfering RNA to the HCV gene by lactosylated cationic liposome", JOURNAL OF HEPATOLOGY, MUNKSGAARD INTERNATIONAL PUBLISHERS, COPENHAGEN, DK LNKD- DOI:10.1016/J.JHEP.2007.06.015, vol. 47, no. 6, 6 November 2007 (2007-11-06), pages 744 - 750, XP022367839, ISSN: 0168-8278 *

Also Published As

Publication number Publication date
WO2009143345A2 (fr) 2009-11-26

Similar Documents

Publication Publication Date Title
WO2009143345A3 (fr) Conjugués agent-protéine désactivant des acides nucléiques et leur utilisation pour traiter des troubles liés au vhc
WO2010030538A3 (fr) Composés destinés au traitement de l'hépatite c
WO2009006297A3 (fr) Procédés de modification du génome d'une cellule de plante monocotylédone
WO2008156987A3 (fr) Riborégulateurs et procédés et composition pour l'utilisation de et avec des riborégulateurs
WO2009055335A3 (fr) Inhibiteurs des protéases du vhc
WO2009006577A3 (fr) Compositions et méthodes pour inhiber la protéine ezh2
WO2007095638A3 (fr) Petites molecules contenant du bore en tant qu'agents anti-inflammatoires
WO2009114810A3 (fr) Utilisation d'ellagitannines comme inhibiteurs de la détection du quorum bactérien
WO2008127364A3 (fr) Composés antiviraux et utilisation de ceux-ci
EP3418386A3 (fr) Compositions et méthodes permettant d'inhiber l'expression d'un gène du virus de l'hépatite b
WO2010141511A3 (fr) Polynucléotides pour interférence arn multivalente, compositions et procédés pour les utiliser
WO2010004197A3 (fr) Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
WO2010056737A3 (fr) Procédés et compositions impliquant des miarn dans des cellules souches cancéreuses
WO2008150897A3 (fr) Réduction de la toxicité de l'interférence arn hors cible
WO2011039511A3 (fr) Agents, utilisations et procédés
WO2008083239A3 (fr) Compositions et procédés pour la stimulation d'une réaction immunitaire
WO2010011343A3 (fr) Procédés de traitement d’affections virales
WO2008115281A3 (fr) Composés de traitement d'infections virales
WO2009026166A3 (fr) Composés de flavonol anti-infectieux et leurs procédés d'utilisation
WO2012138694A3 (fr) Compositions comprenant des fractions de liaison au saccharide et procédés pour une thérapie ciblée
WO2009158432A3 (fr) Inhibition de l’ang-2 pour traiter la sclérose en plaques
EA200970533A1 (ru) Жидкие композиции антител против бешенства
WO2010017154A3 (fr) Modulation de l'expression de récepteur de type toll 3 par des oligonucléotides antisens
WO2010056043A3 (fr) Anticorps à pénétration cellulaire, spécifique de séquence et hydrolysant les acides nucléiques, son procédé de préparation et composition pharmaceutique le contenant
WO2009099877A3 (fr) Vecteurs de closterovirus et procédés

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09751573

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09751573

Country of ref document: EP

Kind code of ref document: A2